{"schema_version":"secwatch.filing_event.v1","accession":"0001570562-24-000127","form_type":"8-K","ticker":"EOLS","cik":"0001570562","company_name":"Evolus, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.828327+00:00","generated_at":"2026-05-30T04:32:48.306545+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Evolus Q3 revenue $61.1M (+22% YoY); narrows FY2024 guidance to $260-266M","bullets":["Q3 net revenue $61.1M, up 22% from $50.0M in Q3 2023; year-to-date growth 33%.","Full-year 2024 revenue guidance narrowed to $260-266M (29-32% YoY growth).","Received EU approval for Estyme HA gels; U.S. PMA for Evolysse under FDA review, launch expected by Sep 2025.","Evolus Rewards loyalty program exceeded 1M enrolled consumers and 2M total redemptions.","Reaffirms positive non-GAAP operating income target for Q4 2024 and full year 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001570562-24-000127","json":"https://secwatch.observer/filing/0001570562-24-000127.json","markdown":"https://secwatch.observer/filing/0001570562-24-000127.md","text":"https://secwatch.observer/filing/0001570562-24-000127.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1570562/000157056224000127/0001570562-24-000127-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1570562/000157056224000127/eols-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:32:48.306545+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}